Researched and trusted in the fertility community
The micronutrients in Impryl® have shown significant live birth outcomes in clinical studies.
Clinical studies compare the effect of one product or procedure in one group of patients against another group that do not receive that product or procedure. These studies are carefully controlled and the groups of patients are matched in terms of age, symptoms, etc. Conducting these trials is the only way to confidently establish the effectiveness of a specific product.
Clinical data from multiple studies proves that men suffering from fertility problems are twice as likely to father a child when taking the active micronutrients in Impryl®.
The data from our study proves that women suffering from fertility problems are almost four times as likely to have a baby when taking the active micronutrients in Impryl.
A study in older women with poor ovarian reserve shows that the micronutrients within Impryl increases AMH levels by 40%, which is a good marker for improved ovarian function and patients became pregnant whilst taking Impryl during the trial. Previously, it was thought that the only way for these women to get pregnant was through donated eggs.
More about Impryl
Latest Infertility Insights
